Interventional Therapy in Refractory Hypertension: An Update

1 Gaziano TA, Bitton A, Anand S, Weinstein MC. International Society of Hypertension. The global cost of nonoptimal blood pressure. J Hypertens 2009;27(7):1472–77. doi:10.1097/HJH.0b013e32832a9ba3. GazianoTA BittonA AnandS WeinsteinMC International Society of Hypertension. The global cost of nonoptimal blood pressure J Hypertens 2009 27 7 1472 77 10.1097/HJH.0b013e32832a9ba3 Open DOISearch in Google Scholar

2 Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol 2021;18(11):785–802. doi:10.1038/s41569-021-00559-8. ZhouB PerelP MensahGA EzzatiM Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension Nat Rev Cardiol 2021 18 11 785 802 10.1038/s41569-021-00559-8 Open DOISearch in Google Scholar

3 Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018;39(33):3021–3104. doi:10.1093/eurheartj/ehy339. WilliamsB ManciaG SpieringW 2018 ESC/ESH guidelines for the management of arterial hypertension Eur Heart J 2018 39 33 3021 3104 10.1093/eurheartj/ehy339 Open DOISearch in Google Scholar

4 NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet 2017;389(10064):37–55. doi:10.1016/S0140-6736(16)31919-5. NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis of 1479 population-based measurement studies with 19·1 million participants Lancet 2017 389 10064 37 55 10.1016/S0140-6736(16)31919-5 Open DOISearch in Google Scholar

5 Rabi DM, McBrien KA, Sapir-Pichhadze R, et al. Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol 2020;36(5): 596–624. doi:10.1016/j.cjca.2020.02.086. RabiDM McBrienKA Sapir-PichhadzeR Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children Can J Cardiol 2020 36 5 596 624 10.1016/j.cjca.2020.02.086 32389335 Open DOISearch in Google Scholar

6 Patel KV, Li X, Kondamudi N, et al. Prevalence of apparent treatment-resistant hypertension in the United States according to the 2017 high blood pressure guideline. Mayo Clin Proc 2019;94(5):776–82. doi:10.1016/j.mayocp.2018.12.033. PatelKV LiX KondamudiN Prevalence of apparent treatment-resistant hypertension in the United States according to the 2017 high blood pressure guideline Mayo Clin Proc 2019 94 5 776 82 10.1016/j.mayocp.2018.12.033 31054605 Open DOISearch in Google Scholar

7 Mahfoud F, Himmel F, Ukena C, Schunkert H, Böhm M, Weil J. Treatment strategies for resistant arterial hypertension. Dtsch Arztebl Int 2011;108(43):725–31. doi:10.3238/arztebl.2011.0725. MahfoudF HimmelF UkenaC SchunkertH BöhmM WeilJ Treatment strategies for resistant arterial hypertension Dtsch Arztebl Int 2011 108 43 725 31 10.3238/arztebl.2011.0725 322141822114648 Open DOISearch in Google Scholar

8 Modolo R, de Faria AP, Almeida A, Moreno H. Resistant or refractory hypertension: Are they different? Curr Hypertens Rep 2014;16(10):485. doi:10.1007/s11906-014-0485-1. ModoloR de FariaAP AlmeidaA MorenoH Resistant or refractory hypertension: Are they different? Curr Hypertens Rep 2014 16 10 485 10.1007/s11906-014-0485-1 25139782 Open DOISearch in Google Scholar

9 Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA. Refractory hypertension: A novel phenotype of antihypertensive treatment failure. Hypertension 2016;67(6):1085–92. doi:10.1161/HYPERTENSIONAHA.116.06587. DudenbostelT SiddiquiM OparilS CalhounDA Refractory hypertension: A novel phenotype of antihypertensive treatment failure Hypertension 2016 67 6 1085 92 10.1161/HYPERTENSIONAHA.116.06587 542529727091893 Open DOISearch in Google Scholar

10 Potthoff SA, Vonend O. Multidisciplinary approach in the treatment of resistant hypertension. Curr Hypertens Rep 2017;19(1):9. doi:10.1007/s11906-017-0698-1. PotthoffSA VonendO Multidisciplinary approach in the treatment of resistant hypertension Curr Hypertens Rep 2017 19 1 9 10.1007/s11906-017-0698-1 28185122 Open DOISearch in Google Scholar

11 Wei FF, Zhang ZY, Huang QF, Staessen JA. Diagnosis and management of resistant hypertension: State of the art. Nat Rev Nephrol 2018;14(7):428–41. doi:10.1038/s41581-018-0006-6. WeiFF ZhangZY HuangQF StaessenJA Diagnosis and management of resistant hypertension: State of the art Nat Rev Nephrol 2018 14 7 428 41 10.1038/s41581-018-0006-6 Open DOISearch in Google Scholar

12 Böhm M, Linz D, Urban D, Mahfoud F, Ukena C. Renal sympathetic denervation: Applications in hypertension and beyond. Nat Rev Cardiol 2013;10(8):465–76. doi:10.1038/nrcardio.2013.89. BöhmM LinzD UrbanD MahfoudF UkenaC Renal sympathetic denervation: Applications in hypertension and beyond Nat Rev Cardiol 2013 10 8 465 76 10.1038/nrcardio.2013.89 Open DOISearch in Google Scholar

13 Mahfoud F, Renkin J, Sievert H, et al. Alcohol-mediated renal denervation using the Peregrine System infusion catheter for treatment of hypertension. JACC Cardiovasc Interv 2020;13(4):471–84. doi:10.1016/j.jcin.2019.10.048. MahfoudF RenkinJ SievertH Alcohol-mediated renal denervation using the Peregrine System infusion catheter for treatment of hypertension JACC Cardiovasc Interv 2020 13 4 471 84 10.1016/j.jcin.2019.10.048 Open DOISearch in Google Scholar

14 Mahfoud F, Edelman E, Bhatt N. Stereotactic radiotherapy for renal denervation: To beam, or not to beam? J Am Coll Cardiol 2019;74(13):1710–13. doi:10.1016/j.jacc.2019.07.054. MahfoudF EdelmanE BhattN Stereotactic radiotherapy for renal denervation: To beam, or not to beam? J Am Coll Cardiol 2019 74 13 1710 13 10.1016/j.jacc.2019.07.054 Open DOISearch in Google Scholar

15 Wei FF, Zhang ZY, Huang QF, Staessen JA. Diagnosis and management of resistant hypertension: State of the art. Nat Rev Nephrol 2018;14(7):428–41. doi:10.1038/s41581-018-0006-6. WeiFF ZhangZY HuangQF StaessenJA Diagnosis and management of resistant hypertension: State of the art Nat Rev Nephrol 2018 14 7 428 41 10.1038/s41581-018-0006-6 Open DOISearch in Google Scholar

16 Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: Durability of blood pressure reduction out to 24 months. Hypertension 2011;57(5): 911–17. doi:10.1161/HYPERTENSIONAHA.110.163014. Symplicity HTN-1 Investigators Catheter-based renal sympathetic denervation for resistant hypertension: Durability of blood pressure reduction out to 24 months Hypertension 2011 57 5 911 17 10.1161/HYPERTENSIONAHA.110.163014 Open DOISearch in Google Scholar

17 Symplicity HTN-2 Investigators, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial. Lancet 2010;376(9756):1903–09. doi:10.1016/S0140-6736(10)62039-9. Symplicity HTN-2 Investigators EslerMD KrumH Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial Lancet 2010 376 9756 1903 09 10.1016/S0140-6736(10)62039-9 Open DOISearch in Google Scholar

18 Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370(15):1393–1401. doi:10.1056/NEJMoa1402670. BhattDL KandzariDE O’NeillWW A controlled trial of renal denervation for resistant hypertension N Engl J Med 2014 370 15 1393 1401 10.1056/NEJMoa1402670 Open DOISearch in Google Scholar

19 Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): A multicentre, open-label, randomised controlled trial. Lancet 2015;385(9981):1957–65. doi:10.1016/S0140-6736(14)61942-5. AziziM SapovalM GosseP Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): A multicentre, open-label, randomised controlled trial Lancet 2015 385 9981 1957 65 10.1016/S0140-6736(14)61942-5 Open DOISearch in Google Scholar

20 Rosa J, Widimský P, Toušek P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: Six-month results from the Prague-15 study. Hypertension 2015;65(2):407–13. doi:10.1161/HYPERTENSIONAHA.114.04019. RosaJ WidimskýP ToušekP Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: Six-month results from the Prague-15 study Hypertension 2015 65 2 407 13 10.1161/HYPERTENSIONAHA.114.04019 25421981 Open DOISearch in Google Scholar

21 Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: A pilot study. Circulation 2011;123(18):1940–46. doi:10.1161/CIRCULATIONAHA.110.991869. MahfoudF SchlaichM KindermannI Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: A pilot study Circulation 2011 123 18 1940 46 10.1161/CIRCULATIONAHA.110.991869 Open DOISearch in Google Scholar

22 Mahfoud F, Mancia G, Schmieder R, et al. Renal denervation in high-risk patients with hypertension. J Am Coll Cardiol 2020;75(23):2879–88. doi:10.1016/j.jacc.2020.04.036. MahfoudF ManciaG SchmiederR Renal denervation in high-risk patients with hypertension J Am Coll Cardiol 2020 75 23 2879 88 10.1016/j.jacc.2020.04.036 Open DOISearch in Google Scholar

23 Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): A multicentre, randomised, sham-controlled trial. Lancet 2020;395(10234):1444–51. doi:10.1016/S0140-6736(20)30554-7. BöhmM KarioK KandzariDE Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): A multicentre, randomised, sham-controlled trial Lancet 2020 395 10234 1444 51 10.1016/S0140-6736(20)30554-7 Open DOISearch in Google Scholar

24 Mahfoud F, Townsend RR, Kandzari DE, et al. Changes in plasma renin activity after renal artery sympathetic denervation. J Am Coll Cardiol 2021;77(23):2909–19. doi:10.1016/j.jacc.2021.04.044. MahfoudF TownsendRR KandzariDE Changes in plasma renin activity after renal artery sympathetic denervation J Am Coll Cardiol 2021 77 23 2909 19 10.1016/j.jacc.2021.04.044 33957242 Open DOISearch in Google Scholar

25 Böhm M, Tsioufis K, Kandzari DE, et al. Effect of heart rate on the outcome of renal denervation in patients with uncontrolled hypertension. J Am Coll Cardiol 2021;78(10):1028–38. doi:10.1016/j.jacc.2021.06.044. BöhmM TsioufisK KandzariDE Effect of heart rate on the outcome of renal denervation in patients with uncontrolled hypertension J Am Coll Cardiol 2021 78 10 1028 38 10.1016/j.jacc.2021.06.044 34474735 Open DOISearch in Google Scholar

26 Hawson J, Harmer JA, Cowan M, et al. Renal denervation for the management of refractory ventricular arrhythmias: A systematic review. JACC Clin Electrophysiol 2021;7(1):100–8. doi:10.1016/j.jacep.2020.07.019. HawsonJ HarmerJA CowanM Renal denervation for the management of refractory ventricular arrhythmias: A systematic review JACC Clin Electrophysiol 2021 7 1 100 8 10.1016/j.jacep.2020.07.019 33478701 Open DOISearch in Google Scholar

27 Sharp TE III, Polhemus DJ, Li Z, et al. Renal denervation prevents heart failure progression via inhibition of the renin-angiotensin system. J Am Coll Cardiol 2018;72(21):2609–21. doi:10.1016/j.jacc.2018.08.2186. SharpTEIII PolhemusDJ LiZ Renal denervation prevents heart failure progression via inhibition of the renin-angiotensin system J Am Coll Cardiol 2018 72 21 2609 21 10.1016/j.jacc.2018.08.2186 30466519 Open DOISearch in Google Scholar

28 Mahfoud F, Böhm M, Schmieder R, et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J 2019;40(42):3474–82. doi:10.1093/eurheartj/ehz118. MahfoudF BöhmM SchmiederR Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry Eur Heart J 2019 40 42 3474 82 10.1093/eurheartj/ehz118 683716030907413 Open DOISearch in Google Scholar

29 Li S, Phillips JK. Patient selection for renal denervation in hypertensive patients: What makes a good candidate? Vasc Health Risk Manag 2022;18:375–86. doi:10.2147/VHRM.S270182. LiS PhillipsJK Patient selection for renal denervation in hypertensive patients: What makes a good candidate? Vasc Health Risk Manag 2022 18 375 86 10.2147/VHRM.S270182 911355335592729 Open DOISearch in Google Scholar

30 Lohmeier TE, Hall JE. Device-based neuromodulation for resistant hypertension therapy. Circ Res 2019;124(7):1071–93. doi:10.1161/CIRCRESAHA.118.313221. LohmeierTE HallJE Device-based neuromodulation for resistant hypertension therapy Circ Res 2019 124 7 1071 93 10.1161/CIRCRESAHA.118.313221 644294230920919 Open DOISearch in Google Scholar

31 Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: Results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011;58(7):765–73. doi:10.1016/j.jacc.2011.06.008. BisognanoJD BakrisG NadimMK Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: Results from the double-blind, randomized, placebo-controlled rheos pivotal trial J Am Coll Cardiol 2011 58 7 765 73 10.1016/j.jacc.2011.06.008 Open DOISearch in Google Scholar

32 Yoruk A, Tankut SS, Gassler JP, Bisognano JD. Present and future of interventional treatment of resistant hypertension. Curr Hypertens Rep 2017;19(1):4. doi:10.1007/s11906-017-0702-9. YorukA TankutSS GasslerJP BisognanoJD Present and future of interventional treatment of resistant hypertension Curr Hypertens Rep 2017 19 1 4 10.1007/s11906-017-0702-9 Open DOISearch in Google Scholar

33 Lobo MD, Sobotka PA, Pathak A. Interventional procedures and future drug therapy for hypertension. Eur Heart J 2017;38(15):1101–11. doi:10.1093/eurheartj/ehw303. LoboMD SobotkaPA PathakA Interventional procedures and future drug therapy for hypertension Eur Heart J 2017 38 15 1101 11 10.1093/eurheartj/ehw303 Open DOISearch in Google Scholar

34 Lobo MD, Sobotka PA, Stanton A, et al. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): A randomised controlled trial Lancet 2015;385(9978):1634–41. doi:10.1016/S0140-6736(14)62053-5. LoboMD SobotkaPA StantonA Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): A randomised controlled trial Lancet 2015 385 9978 1634 41 10.1016/S0140-6736(14)62053-5 Open DOISearch in Google Scholar